EP0524212A1 - Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales - Google Patents

Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales

Info

Publication number
EP0524212A1
EP0524212A1 EP91907059A EP91907059A EP0524212A1 EP 0524212 A1 EP0524212 A1 EP 0524212A1 EP 91907059 A EP91907059 A EP 91907059A EP 91907059 A EP91907059 A EP 91907059A EP 0524212 A1 EP0524212 A1 EP 0524212A1
Authority
EP
European Patent Office
Prior art keywords
group
formulation
optionally
carminic acid
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91907059A
Other languages
German (de)
English (en)
Inventor
Washington Odur Ayuko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RADOPATH PHARMACEUTICALS INTERNATIONAL LIMITED
Original Assignee
RADOPATH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909007453A external-priority patent/GB9007453D0/en
Priority claimed from GB909012166A external-priority patent/GB9012166D0/en
Priority claimed from GB919103075A external-priority patent/GB9103075D0/en
Application filed by RADOPATH Ltd filed Critical RADOPATH Ltd
Publication of EP0524212A1 publication Critical patent/EP0524212A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Composés de radicaux à base de trinitrobenzène, acide carminique et ses dérivés, utilisables comme agents anti-cancer et anti-virus. Ces composés et les formules basées sur ceux-ci, peuvent s'administrer par voie orale ou parentérale à un malade humain ou animal, en solution/suspension aqueuse pratiquement pure dans une plage de dilutions située entre 10-3 et 10-15 en concentrations molaires. Selon une application préférentielle de l'invention, on utilise un ou davantage desdits composés et un anthraquinone (comme l'acide carminique). L'acide carminique seul présente des effets anti-virus notoires.
EP91907059A 1990-04-03 1991-04-03 Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales Withdrawn EP0524212A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9007453 1990-04-03
GB909007453A GB9007453D0 (en) 1990-04-03 1990-04-03 Tumour therapy
GB9012166 1990-05-31
GB909012166A GB9012166D0 (en) 1990-05-31 1990-05-31 Hydrazine derivatives for cancer therapy
GB919103075A GB9103075D0 (en) 1991-02-13 1991-02-13 Trinitrobenzene derivatives and their therapeutic use
GB9103075 1991-02-13

Publications (1)

Publication Number Publication Date
EP0524212A1 true EP0524212A1 (fr) 1993-01-27

Family

ID=27265028

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91907059A Withdrawn EP0524212A1 (fr) 1990-04-03 1991-04-03 Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales

Country Status (11)

Country Link
EP (1) EP0524212A1 (fr)
JP (1) JPH06501449A (fr)
AU (1) AU662883B2 (fr)
BR (1) BR9106310A (fr)
CA (1) CA2079803A1 (fr)
FI (1) FI924475A0 (fr)
HU (1) HUT62785A (fr)
LV (1) LV10574B (fr)
MC (1) MC2246A1 (fr)
NO (1) NO923824L (fr)
WO (1) WO1991015200A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
US5412123A (en) * 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
GB2312375B (en) * 1993-05-21 1998-02-25 Radopath Ltd Agents for treatment of cancer
DZ1781A1 (fr) * 1993-05-21 2002-02-17 Radopah Ltd Agents d'arylation.
GB9310520D0 (en) 1993-05-21 1993-07-07 Radopath Ltd Arylating agents
DE69519722D1 (de) * 1994-03-17 2001-02-01 Radopath Pharmaceuticals Inter Wirkstof gegen viren und krebs
WO1996029067A1 (fr) * 1995-03-17 1996-09-26 Radopath Limited Agents antiviraux et anticancereux
GB9615619D0 (en) * 1996-03-18 1996-09-04 Radopath Ltd Costimulation of TcR/CD3-induced T-Lymphocytes
AU1903699A (en) * 1997-12-08 1999-06-28 Glycomed Incorporated Disalicylate analog based sialyl lewisx mimetics
JP2021530605A (ja) * 2018-07-17 2021-11-11 ピリ アントラキノン系誘導体及び着色剤としてのそれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032659A (en) * 1969-03-20 1977-06-28 American Home Products Corporation Method of viral chemoprophylaxis
CA1262864A (fr) * 1982-09-17 1989-11-14 Clarence D. Cone Methode de production d'une oncolyse
FR2622445B1 (fr) * 1987-10-30 1990-07-27 Pasteur Institut Application de groupes nitrophenyles a la stimulation des capacites d'incorporation d'un medicament dans les cellules sensibles de l'hote

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9115200A2 *

Also Published As

Publication number Publication date
NO923824D0 (no) 1992-10-01
NO923824L (no) 1992-11-26
MC2246A1 (fr) 1993-03-25
HU9203148D0 (en) 1992-12-28
LV10574A (lv) 1995-04-20
LV10574B (en) 1995-08-20
FI924475A (fi) 1992-10-05
AU662883B2 (en) 1995-09-21
FI924475A0 (fi) 1992-10-05
BR9106310A (pt) 1993-04-20
JPH06501449A (ja) 1994-02-17
WO1991015200A2 (fr) 1991-10-17
WO1991015200A3 (fr) 1992-03-05
CA2079803A1 (fr) 1991-10-04
AU7560491A (en) 1991-10-30
HUT62785A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
AU2001230977B2 (en) Combinations for treating neoplasms
NZ240487A (en) Formulations comprising trinitrobenzene derivative and optionally a quinone
AU2001230977A1 (en) Combinations for treating neoplasms
AU662883B2 (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
US6720011B1 (en) Injectable composition for cancer treatment
US5891454A (en) Anti-cancer drug and special tumor necrotizing agent
OA12862A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
NL194430C (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
US6169083B1 (en) Preventives/remedies for stomatitis
EP0717995A2 (fr) Agent supprimant la dégénération de cellules et reduisant la toxicité des organes
Mouridsen et al. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study
US6306901B1 (en) Agent for prophylaxis and therapy of diseases
JP2004315470A (ja) ヨウ化ナトリウム含有製剤
KR100369890B1 (ko) 설사예방및치료제
KR19990063735A (ko) 1,2,4-벤조트리아진 옥사이드 제제
JP2003507334A (ja) 血漿代用組成物
LT3173B (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
RU2211035C1 (ru) Противотуберкулезный препарат
JPS6337767B2 (fr)
RU2257200C1 (ru) Лекарственное средство
JPH04103538A (ja) 制癌剤副作用抑制剤
IE913661A1 (en) Udpg as a rescue agent in cancer therapy after the¹administration of antipyrimidine or related anti-tumor¹agents with or without bau
JPS6227047B2 (fr)
JP2013018729A (ja) アルツハイマー病治療剤の作用増強経口用剤
JPH0672896A (ja) 腎機能改善薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950309

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RADOPATH PHARMACEUTICALS INTERNATIONAL LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991103